Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics Inc (VVOS) provides innovative solutions for sleep-disordered breathing through its proprietary oral appliance therapy and integrated clinical protocols. This news hub offers investors and healthcare professionals direct access to official announcements, financial disclosures, and progress updates on the company's non-invasive treatment alternatives for obstructive sleep apnea.
Our curated collection features regulatory filings, partnership announcements, clinical trial updates, and technology developments. Users will find timely information about the Vivos System implementation, insurance coverage expansions, and research collaborations within the sleep medicine field.
The page organizes content by key categories including quarterly earnings reports, FDA communications, provider network growth, and peer-reviewed study publications. Each update maintains factual accuracy while highlighting the company's position in the $7 billion sleep apnea treatment market.
Bookmark this page for streamlined tracking of Vivos' progress in commercializing its oral appliance technology and expanding its licensed provider network. Check regularly for new developments in patient outcomes data and healthcare provider adoption rates across North America.
Vivos Therapeutics (NASDAQ: VVOS) has released detailed results from a national study on its FDA Class 1 DNA appliance for sleep-disordered breathing. The data indicates that one in four patients reported complete resolution of obstructive sleep apnea (OSA) symptoms. Among 20 patients with severe OSA, average improvement in AHI scores was 53%, with none reporting worsening symptoms. The average improvement for 18 patients with moderate OSA was 64%. The results highlight the effectiveness of Vivos' treatment protocols compared to traditional methods.
Vivos Therapeutics reported a 37.5% increase in Q2 revenue, reaching $4.5 million, and a 30% rise from Q1 2021. Gross profit for Q2 was $3.6 million, with an 81% gross margin. However, the company faced a net loss of $4.0 million for the quarter, up from <$1.4 million> in Q2 2020. Vivos has treated over 19,000 patients and opened a training center in Denver. New initiatives, including the VivoScore test, have shown a significant increase in sleep apnea testing, indicating expanding market adoption.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q3 Virtual Investor Summit on August 18, 2021, at 9:30 am EST. The presentation will feature CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Vivos focuses on developing innovative treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company’s Vivos System offers a non-invasive, cost-effective solution using customized oral appliances, proven effective in over 19,000 patients globally. Interested investors can register for the presentation online.
Vivos Therapeutics (NASDAQ: VVOS) will release its second-quarter financial results after market close on August 12, 2021, with a conference call scheduled for 5:00 p.m. ET the same day. This call will cover the company's financial performance, recent milestones, and growth strategy. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly obstructive sleep apnea. The company offers the Vivos System, a non-invasive oral appliance treatment that has benefitted over 19,000 patients worldwide through 1,250 dentists.
Vivos Therapeutics has announced the opening of The Vivos Institute in Denver, Colorado. This 15,000-square-foot training facility aims to significantly enhance education for healthcare providers on treating obstructive sleep apnea (OSA). The Institute can train 300 to 400 professionals daily, offering hands-on education about OSA and Vivos’ treatments. Key funding of over $500,000 in equipment was donated by dental and medical supply companies. The opening is part of Vivos' mission to improve awareness and treatment options for sleep-disordered breathing.
Vivos Therapeutics (NASDAQ: VVOS) announced results from a national study involving 74 adult patients with obstructive sleep apnea (OSA) treated with its FDA Class 1 DNA appliance. The study revealed that 28% of patients reported no remaining OSA symptoms post-treatment. Additionally, 82% showed improvement in their Apnea Hypopnea Index (AHI) scores, with 64% improving by at least one category. The average treatment lasted 14 months, and findings have been submitted to the FDA for 510k clearance. Vivos believes their technology may be a breakthrough for OSA treatment.
Vivos Therapeutics (NASDAQ: VVOS) announced positive results from an independent patient survey regarding its treatment for obstructive sleep apnea (OSA). Key findings show that 97% of patients achieved their desired outcomes with Vivos treatment, while 63% sought dentists' advice for solutions. The treatment typically lasts 12 to 24 months and addresses dental tissue anomalies linked to OSA, providing a non-invasive alternative to CPAP. The survey involved 123 patients and was executed by The EyeDeas Company in June 2021.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced the release of a new book by its Founder and Chief Medical Officer, Dr. G. Dave Singh, aimed at helping medical professionals understand craniofacial conditions affecting sleep health. The book, titled Pneumopedics and Craniofacial Epigenetics, explores the link between dentofacial anomalies and obstructive sleep apnea (OSA). Vivos’ technology offers a non-invasive treatment for mild-to-moderate OSA, now proven effective in over 17,000 patients. The book serves as a culmination of Dr. Singh's research and aims to advance understanding of innovative therapy options.
Vivos Therapeutics (NASDAQ: VVOS) reported its Q1 2021 financial results, revealing a revenue of $3.4 million, an 8% increase from Q1 2020. Gross profit rose by 11% to $2.7 million with a gross margin of 78%. However, net loss increased to $3.4 million from $2.6 million year-over-year. The company bolstered its finances with a follow-on offering generating $27.6 million in May. Recent developments include the launch of AireO2 software and VivoScore home testing services, along with the opening of Pneusomnia Centers aimed at enhancing treatment options for sleep disorders.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its first-quarter financial results for 2021 on May 17, 2021, after market close. A conference call is scheduled for the same day at 5:00 PM ET, where the company will discuss its financial performance and growth strategy. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA). Their Vivos System has been effective for over 15,000 patients worldwide through customized oral appliances.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
